Thyroid Eye Disease
Pipeline by Development Stage
Drug Modality Breakdown
Endocrinology is a $1.4B mature market dominated by legacy products and characterized by significant patent cliff exposure in the near-term.
Key Trends
- Two blockbusters (FORTEO, SYNTHROID) approaching LOE with $780M combined spend
- Growth phase products (ORGOVYX, TYMLOS) entering peak revenue years through 2040
- Heavy trial activity (625 total) concentrated in Phase 3 and Phase 4 studies indicating established disease focus
Career Verdict
Endocrinology offers stability and specialized expertise but limited growth upside; best suited for professionals comfortable in mature markets seeking deep disease knowledge rather than explosive market expansion.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | FORTEO (TERIPARATIDE) | Eli Lilly and Company | $425M | 30% | LOE_APPROACHING | Declining | |
| 2 | SYNTHROID (LEVOTHYROXINE SODIUM) | AbbVie | $355M | 25% | LOE_APPROACHING | Declining | |
| 3 | ORGOVYX (RELUGOLIX) | Sumitomo Dainippon Pharma | $277M | 20% | PEAK | Stable | 11.4yr |
| 4 | TYMLOS (ABALOPARATIDE) | Radius Health | $198M | 14% | PEAK | Stable | 13.7yr |
Drug Class Breakdown
LOE approaching; potential for new mechanisms
Mature, multiple generics; limited differentiation
Growth trajectory through 2037
Stable; multiple biosimilars in market
Emerging niche for rare endocrine disorders
Career Outlook
StableEndocrinology offers deep specialization and stable employment but limited growth trajectory; market maturity and patent cliff exposure create restructuring risk for legacy product teams at large pharma. Career advancement depends on niche expertise (rare endocrine disorders, bone metabolism) and willingness to work at smaller or specialist biotech firms where hiring is concentrated. Compensation is moderate relative to other therapeutic areas, with Medical Affairs and Clinical Operations commanding premiums.
Breaking In
Prioritize roles at Neurocrine Biosciences or other specialist firms over large pharma to gain endocrinology depth; seek Clinical Operations or IT positions for better compensation and career stability.
For Experienced Professionals
Experienced professionals should pursue Medical Affairs or senior Clinical Operations roles (highest salaries) or consider pivoting to emerging indications (GnRH antagonists in non-prostate oncology, novel PTH mechanisms) to avoid legacy product decline.
In-Demand Skills
Best For
Hiring Landscape
Endocrinology hiring is concentrated at specialist biotech firms (Neurocrine: 126 jobs, 93% of available positions) rather than large pharma, indicating a niche market dynamic. IT roles dominate openings (51 jobs, $201K avg) followed by R&D (21 jobs, $120K avg), suggesting company-level digitalization and data infrastructure needs. Compensation ranges widely ($115K-$359K), with Medical Affairs offering premium salaries ($359K) but minimal openings (6 jobs).
By Department
Limited total opportunity (135 jobs) concentrated at one biotech firm signals a tight job market; IT and Clinical Operations offer best compensation, but specialized endocrinology roles are scarce.
On Market (1)
Approved therapies currently available
Competitive Landscape
15 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 37 trials with date data
Clinical Trials (38)
Total enrollment: 3,050 patients across 38 trials
A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease
TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study
Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease
A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease
A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)
A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease
A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)
A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.
A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease
An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301
An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) (THRIVE-2)
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants With Thyroid Eye Disease (TED) ( THRIVE )
A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)
Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study
Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
A Study of IBI311 in Subjects With Active Thyroid Eye Disease
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease
A Study of IBI311 in Subjects With Inactive or Active Thyroid Eye Disease
A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease
A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese Participants
Evaluation of K9 in Subjects With Thyroid Eye Disease (TED)
A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease
Study of ZB001 in Chinese Patients With Thyroid Eye Disease
A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants
A Study of TEPEZZA® Treatment in Participants With Thyroid Eye Disease
A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)
Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease
Real World Study to Describe the Effectiveness and Safety of Teprotumumab Among Thyroid Eye Disease Patients
Twenty-four Hour Intraocular Pressure Patterns in Patients With Uncontrolled Thyroid Eye Disease
Related Jobs in Endocrinology
Group Leader - Senior Director, Quantitative Pharmacology and Pharmacometrics (Hybrid or Remote)
Director, Marketing Operations
SPM
Sr. Consultant, Data Analyst & Commercial Productivity
Area Business Manager - Central Alabama
Grants Manager
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.